Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic.

COVID-19 AND NEUROLOGY Because most patients with MG are on immunosuppressive or immunomodulatory therapies and may also have respiratory muscle weakness, there is a theoretical concern that MG/LEMS patients may be at higher risk of contracting the infection or experiencing…

Because most patients with MG are on immunosuppressive or immunomodulatory therapies and may also have respiratory muscle weakness, there is a theoretical concern that MG/LEMS patients may be at higher risk of contracting the infection or experiencing severe manifestations of COVID-19. In addition, to date, peer reviewed published literature regarding COVID-19 in MG or in immunocompromised patients is lacking. In this very useful short communication, the International MG/COVID-19 Working Group has developed recommendations about the management of MG and LEMS patients during the COVID-19 pandemic. In particular, the MG expert panel suggests that therapy decisions should be individualized and made collaboratively between the patients with MG and his/her healthcare provider. 

https://www.ncbi.nlm.nih.gov/pubmed/32247193

by Marialuisa Zedde and Francesco Cavallieri